PROGRESSION IN UNTREATED CARCINOMA OF THE PROSTATE METASTATIC TO REGIONAL LYMPH-NODES (STAGE T0 4,N1 TO 3,M0,D1)

被引:34
作者
DAVIDSON, PJT
HOP, W
KURTH, KH
FOSSA, SD
WAEHRE, H
SCHRODER, FH
机构
[1] ERASMUS UNIV ROTTERDAM,DEPT UROL,3000 DR ROTTERDAM,NETHERLANDS
[2] ERASMUS UNIV ROTTERDAM,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS
[3] ACAD HOSP,ROTTERDAM,NETHERLANDS
[4] UNIV AMSTERDAM,ACAD MED CTR,DEPT UROL,1105 AZ AMSTERDAM,NETHERLANDS
[5] NORWEGIAN RADIUM HOSP,DEPT RADIOTHERAPY,OSLO,NORWAY
关键词
PROSTATE; ADENOCARCINOMA; LYMPH NODES; NEOPLASM METASTASES; PROSTATIC NEOPLASMS;
D O I
10.1016/S0022-5347(01)66711-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We attempt to contribute to the understanding of the natural history of prostate cancer metastatic to lymph nodes. Materials and Methods: A total of 61 patients with node-positive prostate cancer was prospectively followed without adjuvant treatment for an average of 41 months. The impact of T and P categories, grade, tumor volume and prostate specific antigen change on interval to progression was studied in a univariate and multivariate analysis. Results: Median interval to progression was 18 months, and correlated with grade and prostate specific antigen doubling time. Changes in prostatic volume with time were not predictive. Conclusions: Our study provides insight into the natural history of node-positive disease and identifies relevant prognostic factors that may be used for treatment decisions.
引用
收藏
页码:2118 / 2122
页数:5
相关论文
共 33 条
[1]   PROGNOSTIC-SIGNIFICANCE OF EXTENT OF NODAL INVOLVEMENT IN STAGE-D1 PROSTATE-CANCER TREATED WITH RADIOTHERAPY [J].
ANSCHER, MS ;
PROSNITZ, LR .
UROLOGY, 1992, 39 (01) :39-43
[2]  
BAILAR JC, 1970, CANCER, V26, P257, DOI 10.1002/1097-0142(197008)26:2<257::AID-CNCR2820260203>3.0.CO
[3]  
2-9
[4]  
BRAWN P, 1990, CANCER-AM CANCER SOC, V65, P538, DOI 10.1002/1097-0142(19900201)65:3<538::AID-CNCR2820650326>3.0.CO
[5]  
2-G
[6]   LONGITUDINAL EVALUATION OF PROSTATE-SPECIFIC ANTIGEN LEVELS IN MEN WITH AND WITHOUT PROSTATE DISEASE [J].
CARTER, HB ;
PEARSON, JD ;
METTER, J ;
BRANT, LJ ;
CHAN, DW ;
ANDRES, R ;
FOZARD, JL ;
WALSH, PC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (16) :2215-2220
[7]   INTERMEDIATE-TERM SURVIVAL RESULTS IN CLINICALLY UNDERSTAGED PROSTATE-CANCER PATIENTS FOLLOWING RADICAL PROSTATECTOMY [J].
CATALONA, WJ ;
MILLER, DR ;
KAVOUSSI, LR .
JOURNAL OF UROLOGY, 1988, 140 (03) :540-543
[8]  
CHENG CWS, 1993, CANCER, V71, P996, DOI 10.1002/1097-0142(19930201)71:3+<996::AID-CNCR2820711417>3.0.CO
[9]  
2-8
[10]  
COX DR, 1972, J R STAT SOC B, V34, P187